Prior to initiation of the targeted therapy with HLEAFab-MMC, the expression of LMP1 was evaluated with IHC and in situ hybridization (ISH) in samples from 36 NPC patients. This evidence concerns the gene PDLIM7 and nasopharyngeal carcinoma.